OLMA Olema Pharmaceuticals, Inc.

Nasdaq olema.com


$ 7.83 $ -1.59 (-16.99 %)    

Monday, 20-Oct-2025 18:42:01 EDT
QQQ $ 611.41 $ 0.00 (0 %)
DIA $ 466.46 $ 0.00 (0 %)
SPY $ 670.99 $ 0.00 (0 %)
TLT $ 91.77 $ 0.00 (0 %)
GLD $ 393.20 $ 0.00 (0 %)
$ 7.77
$ 7.28
$ 7.90 x 190
$ 8.00 x 107
-- - --
$ 2.86 - $ 13.51
5,812,318
na
666.11M
$ 2.03
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-11-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-18-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 03-11-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-09-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-10-2021 06-30-2021 10-Q
18 05-11-2021 03-31-2021 10-Q
19 03-17-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-olema-pharmaceuticals-maintains-28-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and maintains $28 pri...

 reported-saturday-olema-oncology-reports-155-month-median-progression-free-survival-with-palazestrant-plus-ribociclib-in-er-positive-her2-negative-metastatic-breast-cancer-at-esmo-2025

Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroupsMedian PFS w...

 guggenheim-initiates-coverage-on-olema-pharmaceuticals-with-buy-rating-announces-price-target-of-20

Guggenheim analyst Brad Canino initiates coverage on Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy rating and announces Pri...

 oppenheimer-maintains-outperform-on-olema-pharmaceuticals-maintains-22-price-target

Oppenheimer analyst Matthew Biegler maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Outperform and maintains $22 price ...

 jp-morgan-maintains-overweight-on-olema-pharmaceuticals-raises-price-target-to-29

JP Morgan analyst Anupam Rama maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Overweight and raises the price target fr...

 citigroup-maintains-buy-on-olema-pharmaceuticals-raises-price-target-to-21

Citigroup analyst Yigal Nochomovitz maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and raises the price target fro...

 olema-pharmaceuticals-q2-eps-051-misses-038-estimate

Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate ...

 goldman-sachs-maintains-buy-on-olema-pharmaceuticals-lowers-price-target-to-18

Goldman Sachs analyst Richard Law maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from ...

 oppenheimer-maintains-outperform-on-olema-pharmaceuticals-lowers-price-target-to-22

Oppenheimer analyst Matthew Biegler maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Outperform and lowers the price tar...

 olema-pharmaceuticals-q1-eps-036-beats-051-estimate

Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of...

 hc-wainwright--co-reiterates-buy-on-olema-pharmaceuticals-maintains-30-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and maintains $30 pri...

 jp-morgan-maintains-overweight-on-olema-pharmaceuticals-lowers-price-target-to-28

JP Morgan analyst Anupam Rama maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Overweight and lowers the price target fr...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION